Safety of Cetirizine with Montelukast in Second Trimester Pregnancy
Both cetirizine and montelukast can be used during the second trimester of pregnancy, with cetirizine being the preferred antihistamine and montelukast reserved for when conventional medications fail to control symptoms.
Cetirizine Safety Profile
Cetirizine demonstrates a favorable safety profile during pregnancy, including the second trimester:
- Cetirizine and loratadine are the second-generation antihistamines of choice during pregnancy 1, 2
- Large population studies covering over 186,000 exposures in Scandinavian registries found no statistically significant associations with major congenital malformations, spontaneous abortions, or preterm births 3
- Prospective cohort studies show no increased risk of major malformations compared to non-teratogenic exposures 4, 5
- The medication is classified as "probably safe" during the second and third trimesters 2
Montelukast Safety Profile
Montelukast has more limited but generally reassuring data:
- FDA Pregnancy Category B - animal studies show no teratogenicity at doses up to 400 mg/kg in rats and 300 mg/kg in rabbits (100-110 times human exposure) 6
- Limited human data suggest no significantly increased risk of malformations, though the number of exposed women is insufficient to ensure complete fetal safety 2
- A 2024 meta-analysis found no significant increase in major congenital anomalies (RR 1.13,95% CI 0.74-1.73, p=0.56) 7
- Important caveat: Montelukast may be associated with preterm delivery and low birthweight (OR 1.82,95% CI 1.35-2.45) 7
- Rare cases of limb reduction defects have been reported, though causality is not established 2, 6
Clinical Recommendations
For second trimester use:
- Cetirizine is appropriate as first-line therapy for allergic rhinitis and can be used without significant concern 1, 2, 8
- Montelukast should be used when conventional medications fail to secure symptom control 2, particularly for asthma management where the maternal benefit of controlled asthma outweighs potential risks
- The combination can be used when clinically indicated, as both medications have acceptable safety profiles in the second trimester
Important Caveats
- While montelukast crosses the placenta 6, the major benefit in severe asthma or uncontrolled allergic disease typically exceeds possible fetal risk
- Uncontrolled maternal asthma poses definite risks to both mother and fetus 1, making treatment essential
- Monitor for signs of preterm labor if using montelukast, given the association with preterm delivery 7
- Healthcare providers should report any prenatal exposure to montelukast to the pregnancy registry at (800) 986-8999 6
The combination therapy is clinically reasonable in the second trimester when symptom control requires both medications, with cetirizine having the stronger safety evidence and montelukast being acceptable when needed for adequate disease control 1, 2, 8.